Festival of Biologics

Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow

May 6th 2025

Article

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.

Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships

April 29th 2025

Article

Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.

FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access

April 28th 2025

Article

Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.

Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market

April 25th 2025

Article

Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.

Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes

April 24th 2025

Article

Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.

Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain

April 24th 2025

Article

Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.

Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report

May 19th 2024

Podcast

The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.

AON Saves Over $243 Million With High Biosimilar Adoption

April 22nd 2024

Article

Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.

The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability

April 16th 2024

Article

Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.

A Long Time Coming: Dr Sophia Humphreys Details What’s Coming Down the Biosimilar Pipeline

March 23rd 2023

Article

In the wake of adalimumab biosimilars hitting the US market, Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health, hyped up the current biosimilar market trends and the other products coming down the pipeline during her talk at the Festival of Biologics.

x